NeuroOne® OneRF® Technology Success Story Featured on Fox News

Pediatric Patient Treated with OneRF ® Ablation System Goes From Up to 10 Nightly Seizures to Zero

EDEN PRAIRIE, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that its proprietary OneRF ® Ablation System was recently featured in a national Fox News article highlighting the successful treatment of a pediatric epilepsy patient.

The article shares the story of 17-year-old Clara Fuller, who previously experienced up to 10 seizures per night due to a rare, medication-resistant form of epilepsy. Clara made history as the first pediatric patient to undergo treatment using NeuroOne’s OneRF ® technology, which enables the minimally invasive radiofrequency ablation of seizure-causing brain tissue. Since the procedure, Clara has been completely seizure-free, enjoying uninterrupted sleep and a return to everyday teenage life.

The full article, published April 11, 2025, is available at: https://www.foxnews.com/tech/teen-goes-from-10-nightly-seizures-zero-brain-implant

“We are honored to have our technology play a role in changing Clara’s life,” said Dave Rosa, CEO of NeuroOne. “This feature reinforces the benefits of the OneRF ® platform and our commitment to advancing minimally invasive solutions for patients living with debilitating neurological conditions.”

To learn more about NeuroOne and its groundbreaking work in epilepsy treatment, as well as the potential for our OneRF ® platform to be used in drug delivery and pain management, please visit nmtc1.com .

About NeuroOne

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com .

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding our business strategy, market size, and potential growth opportunities. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

Caution: Federal law restricts this device to sale by or on the order of a physician.

IR Contact MZ Group – MZ North America NMTC@mzgroup.us